Inhibrx Biosciences Q4 net loss narrows as expenses fall

Reuters

Mar 20

<a href="https://laohu8.com/S/INBX">Inhibrx Biosciences</a> Q4 net loss narrows as expenses fall

Overview

Biopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declined
Company's R&D and G&A expenses fell due to lower clinical trial and legal costs
Company ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026

Result Drivers

LOWER CLINICAL TRIAL COSTS - Co said Q4 R&D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completion
REDUCED CONTRACT MANUFACTURING - Co attributed lower R&D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106
CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&A expenses dropped as legal proceedings ended, removing prior period costs

Company press release: ID:nPn7j3qZ1a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS	Miss	-$2.11	-$2.08 (1 Analyst)
Q4 Net Income	Miss	-$32.83 mln	-$32.22 mln (1 Analyst)
Q4 Operating Income	Beat	-$30.92 mln	-$34.15 mln (1 Analyst)
Q4 Operating Expenses		$30.92 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620276227"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620276227\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620276227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620276227","market":"nz","top_or_hot":-1,"title":"Inhibrx Biosciences Q4 net loss narrows as expenses fall","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Q4 net loss narrows as expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declined</p></li><li><p>Company's R&amp;D and G&amp;A expenses fell due to lower clinical trial and legal costs</p></li><li><p>Company ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER CLINICAL TRIAL COSTS - Co said Q4 R&amp;D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completion</p></li><li><p>REDUCED CONTRACT MANUFACTURING - Co attributed lower R&amp;D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106</p></li><li><p>CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&amp;A expenses dropped as legal proceedings ended, removing prior period costs</p></li></ul><p>Company press release: <span>ID:nPn7j3qZ1a</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Miss</p></td><td><p>-$2.11</p></td><td><p>-$2.08 (1 Analyst)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Miss</p></td><td><p>-$32.83 mln</p></td><td><p>-$32.22 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td><p>Beat</p></td><td><p>-$30.92 mln</p></td><td><p>-$34.15 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$30.92 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences Q4 net loss narrows as expenses fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences Q4 net loss narrows as expenses fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 04:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Q4 net loss narrows as expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declined</p></li><li><p>Company's R&amp;D and G&amp;A expenses fell due to lower clinical trial and legal costs</p></li><li><p>Company ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER CLINICAL TRIAL COSTS - Co said Q4 R&amp;D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completion</p></li><li><p>REDUCED CONTRACT MANUFACTURING - Co attributed lower R&amp;D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106</p></li><li><p>CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&amp;A expenses dropped as legal proceedings ended, removing prior period costs</p></li></ul><p>Company press release: <span>ID:nPn7j3qZ1a</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Miss</p></td><td><p>-$2.11</p></td><td><p>-$2.08 (1 Analyst)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Miss</p></td><td><p>-$32.83 mln</p></td><td><p>-$32.22 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td><p>Beat</p></td><td><p>-$30.92 mln</p></td><td><p>-$34.15 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$30.92 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL1N4071FD:1","article_id":"2620276227","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620276227","pubTimestamp":1773950987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inhibrx Biosciences Q4 net loss narrows as expenses fallOverviewBiopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declinedCompany's R&D and G&A expenses fell due to lower ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"随着费用下降，Inhibrx Biosciences第四季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":0.9},"content_text":"Inhibrx Biosciences Q4 net loss narrows as expenses fallOverviewBiopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declinedCompany's R&D and G&A expenses fell due to lower clinical trial and legal costsCompany ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026Result DriversLOWER CLINICAL TRIAL COSTS - Co said Q4 R&D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completionREDUCED CONTRACT MANUFACTURING - Co attributed lower R&D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&A expenses dropped as legal proceedings ended, removing prior period costsCompany press release: ID:nPn7j3qZ1aKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPSMiss-$2.11-$2.08 (1 Analyst)Q4 Net IncomeMiss-$32.83 mln-$32.22 mln (1 Analyst)Q4 Operating IncomeBeat-$30.92 mln-$34.15 mln (1 Analyst)Q4 Operating Expenses$30.92 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}